Payment overview · 2025
General Payments
$552.99
23 reported records · 7 companies
Healthcare provider profile · identity verified
William Sulaka, MD
Allopathic & Osteopathic Physicians|Internal Medicine · TROY, MI · NPI 1639309131
Verified facts
What the public records show
CMS Open Payments records show William Sulaka, MD received $552.99 in general payments during 2025 across 23 reported records.
Novo Nordisk Inc accounted for 24.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 23 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Abrysvo, Eliquis, Ozempic, Rybelsus, Shingrix, Synthroid, Trelegy Ellipta, Ubrelvy.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Synthroid by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported UBRELVY as an associated drug or biological on 299803 records involving 61203 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Ubrelvy by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Farxiga by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SHINGRIX as an associated drug or biological on 43515 records involving 26794 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Shingrix by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Trelegy Ellipta by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 91 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 78 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 117 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $136.12 | 24.6% | 9 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $121.35 | 21.9% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $93.33 | 16.9% | 5 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $67.32 | 12.2% | 3 | 2025 |
| Intra-Sana Laboratories | Unresolved — no canonical attribution shown | $66.91 | 12.1% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $36.79 | 6.7% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $31.17 | 5.6% | 2 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $552.99 | 23 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $122.03 | 8 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $122.03 | 8 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $121.35 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $67.32 | 3 | 2025 |
Source payment records
|
|||||
| GLYCATE Normalized: glycate |
Drug | Intra-Sana Laboratories | $66.91 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 200 MG Normalized: reltone 200 mg |
Drug | Intra-Sana Laboratories | $66.91 | 1 | 2025 |
Source payment records
|
|||||
| RELTONE 400 MG Normalized: reltone 400 mg |
Drug | Intra-Sana Laboratories | $66.91 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $58.49 | 3 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $58.49 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $58.49 | 3 | 2025 |
Source payment records
|
|||||
| SYNTHROID Normalized: synthroid |
Drug | ABBVIE INC. | $49.57 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $34.84 | 2 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $20.70 | 1 | 2025 |
Source payment records
|
|||||
| BEXSERO Normalized: bexsero |
Biological | GlaxoSmithKline, LLC. | $20.70 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $20.70 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $17.96 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $17.75 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $16.88 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $16.61 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $16.09 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $14.56 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $14.56 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $14.09 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ABRYSVO abrysvo |
2025 | Abrysvo | 2024 | 78 | exact normalized | Medicare Part D |
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 117 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 91 | exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 14 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| SHINGRIX shingrix |
2025 | Shingrix | 2024 | 22 | exact normalized | Medicare Part D |
| SYNTHROID synthroid |
2025 | Synthroid | 2024 | 36 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| UBRELVY ubrelvy |
2025 | Ubrelvy | 2024 | 20 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
36 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | UBRELVY open payments reported associated product |
CMS Open Payments — General Payments 299803 supporting records · 61203 recipient NPIs · example record 1201352530 |
Ubrelvy · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | SHINGRIX open payments reported associated product |
CMS Open Payments — General Payments 43515 supporting records · 26794 recipient NPIs · example record 1190332452 |
Shingrix · 2024 Exact normalized brand match · 1 Part D row |
22 | 20 |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
91 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
78 | 78 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
117 | 29 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
33 | 33 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 816 | 218 |
| Amlodipine Besylate | Amlodipine Besylate | 500 | 131 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 419 | 121 |
| Losartan Potassium | Losartan Potassium | 385 | 99 |
| Levothyroxine Sodium | Levothyroxine Sodium | 333 | 93 |
| Omeprazole | Omeprazole | 329 | 102 |
| Alprazolam | Alprazolam | 214 | 51 |
| Escitalopram Oxalate | Escitalopram Oxalate | 210 | 51 |
| Metoprolol Succinate | Metoprolol Succinate | 198 | 52 |
| Lisinopril | Lisinopril | 196 | 58 |
| Metformin Hcl | Metformin Hcl | 190 | 55 |
| Simvastatin | Simvastatin | 167 | 45 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 151 | 42 |
| Pantoprazole Sodium | Pantoprazole Sodium | 133 | 37 |
| Hydrochlorothiazide | Hydrochlorothiazide | 126 | 42 |
| Carvedilol | Carvedilol | 120 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 120 | 37 |
| Eliquis | Apixaban | 117 | 29 |
| Gabapentin | Gabapentin | 117 | 28 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 107 | 45 |
| Fluticasone Propionate | Fluticasone Propionate | 100 | 41 |
| Ozempic | Semaglutide | 91 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 86 | 25 |
| Ipratropium Bromide | Ipratropium Bromide | 83 | 21 |
| Chlorthalidone | Chlorthalidone | 82 | 28 |
| Montelukast Sodium | Montelukast Sodium | 82 | 24 |
| Azelastine Hcl | Azelastine Hcl | 79 | 36 |
| Nifedipine Er | Nifedipine | 79 | 22 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 78 | 78 |
| Ezetimibe | Ezetimibe | 76 | 23 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 75 | 14 |
| Jardiance | Empagliflozin | 72 | 16 |
| Zolpidem Tartrate | Zolpidem Tartrate | 70 | 21 |
| Allopurinol | Allopurinol | 69 | 18 |
| Furosemide | Furosemide | 69 | 22 |
| Pravastatin Sodium | Pravastatin Sodium | 69 | 21 |
| Spironolactone | Spironolactone | 68 | 18 |
| Meloxicam | Meloxicam | 67 | 25 |
| Clopidogrel | Clopidogrel Bisulfate | 66 | 19 |
| Metformin Hcl Er | Metformin Hcl | 64 | 23 |
| Famotidine | Famotidine | 63 | 20 |
| Atenolol | Atenolol | 62 | 12 |
| Potassium Chloride | Potassium Chloride | 55 | 18 |
| Clonazepam | Clonazepam | 52 | 15 |
| Trazodone Hcl | Trazodone Hcl | 50 | 15 |
| Irbesartan | Irbesartan | 49 | 11 |
| Tramadol Hcl | Tramadol Hcl | 49 | 19 |
| Prednisone | Prednisone | 46 | 41 |
| Diazepam | Diazepam | 45 | 15 |
| Sertraline Hcl | Sertraline Hcl | 45 | 13 |
| Azithromycin | Azithromycin | 44 | 43 |
| Diclofenac Sodium | Diclofenac Sodium | 43 | 20 |
| Duloxetine Hcl | Duloxetine Hcl | 43 | 11 |
| Methocarbamol | Methocarbamol | 42 | 17 |
| Glimepiride | Glimepiride | 39 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 38 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 38 | suppressed |
| Trulicity | Dulaglutide | 37 | 11 |
| Synthroid | Levothyroxine Sodium | 36 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 35 | suppressed |
| Memantine Hcl | Memantine Hcl | 34 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 34 | 16 |
| Paxlovid | Nirmatrelvir/Ritonavir | 33 | 33 |
| Bupropion Xl | Bupropion Hcl | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 31 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 31 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 31 | suppressed |
| Xarelto | Rivaroxaban | 31 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 30 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 30 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 30 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 30 | 23 |
| Finasteride | Finasteride | 29 | suppressed |
| Lactulose | Lactulose | 29 | 15 |
| Breo Ellipta | Fluticasone/Vilanterol | 26 | suppressed |
| Cefuroxime | Cefuroxime Axetil | 25 | 21 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 25 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 24 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 24 | suppressed |
| Mounjaro | Tirzepatide | 24 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 23 | suppressed |
| Nystatin | Nystatin | 23 | 15 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 22 | 21 |
| Farxiga | Dapagliflozin Propanediol | 22 | suppressed |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 22 | 20 |
| Meclizine Hcl | Meclizine Hcl | 21 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 21 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 20 | suppressed |
| Levetiracetam | Levetiracetam | 20 | suppressed |
| Ubrelvy | Ubrogepant | 20 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 19 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 19 | suppressed |
| Mupirocin | Mupirocin | 19 | 15 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 19 | 17 |
| Fluconazole | Fluconazole | 18 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Lorazepam | Lorazepam | 18 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 18 | 11 |
| Pregabalin | Pregabalin | 18 | suppressed |
| Valsartan | Valsartan | 18 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 18 | suppressed |
| Aripiprazole | Aripiprazole | 17 | suppressed |
| Bumetanide | Bumetanide | 17 | suppressed |
| Celecoxib | Celecoxib | 17 | suppressed |
| Temazepam | Temazepam | 17 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 17 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Colchicine | Colchicine | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Junel Fe | Norethindrone-E.Estradiol-Iron | 16 | suppressed |
| Novolog Flexpen | Insulin Aspart | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 15 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 15 | suppressed |
| Mirtazapine | Mirtazapine | 15 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 15 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 15 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 15 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 13 |
| Rybelsus | Semaglutide | 14 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 13 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 13 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Propranolol Hcl Er | Propranolol Hcl | 13 | suppressed |
| Ultra-Fine Micro Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Zolpidem Tartrate Er | Zolpidem Tartrate | 13 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 12 | suppressed |
| Eszopiclone | Eszopiclone | 12 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 12 | suppressed |
| Ibuprofen | Ibuprofen | 12 | suppressed |
| Levetiracetam Er | Levetiracetam | 12 | suppressed |
| Mesalamine | Mesalamine | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | suppressed |
| Topiramate | Topiramate | 12 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 12 | suppressed |
| Baclofen | Baclofen | 11 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 11 | suppressed |
| Ketoconazole | Ketoconazole | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 11 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 11 | suppressed |
| Nadolol | Nadolol | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $552.99 · 23 records | Novo Nordisk Inc | ABRYSVO, AIRSUPRA, AREXVY, BEXSERO, COMIRNATY, ELIQUIS, EVENITY, GLYCATE, NURTEC ODT, OTEZLA, Ozempic, PREVNAR 20, QULIPTA, RELTONE 200 MG, RELTONE 400 MG, REPATHA, Rybelsus, SHINGRIX, SYNTHROID, TRELEGY ELLIPTA, UBRELVY, Wegovy, ZAVZPRET | 10 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Abrysvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error